Want to join the conversation?
$MRK said the US FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for KEYTRUDA, an anti-PD-1 therapy for treating patients with advanced non-small cell lung cancer whose tumors express PD-L1, with a target action date of Dec. 24. FDA also granted Breakthrough Therapy Designation for this indication.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)